Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aqua Metals, Inc.AQMS · Entity 7979 | Chief Financial Officer | June 15, 2018 | June 18, 2018 |
| Beeline Holdings, Inc.BLNE · Entity 7378 | Director | September 08, 2026 | September 10, 2026 |
| CDT Equity Inc.MURF · Entity 1035 | Director | February 02, 2022 | February 11, 2022 |
| Endovia Health Sciences, Inc.SBEV · Entity 8508 | Director | June 08, 2026 | June 10, 2026 |
| FORUM MARKETS IncATNF · Entity 7020 | Director | September 04, 2023 | September 08, 2023 |
| Innovation1 Biotech Inc.IVBT · Entity 82599 | Director · Chairman and Interim CEO | November 01, 2024 | February 04, 2025 |
| OS Therapies IncOSTX · Entity 6950 | Chief Financial Officer | September 29, 2026 | October 05, 2026 |
| OceanTech Acquisitions I Corp.OTEC · Entity 112900 | Chief Financial Officer | March 13, 2023 | April 21, 2023 |
| Relativity Acquisition CorpRACYU · Entity 116251 | Director | February 10, 2022 | February 10, 2022 |
| SCWorx Corp.WORX · Entity 8668 | Director | November 26, 2019 | November 29, 2019 |
| SPINDLE, INC.SPDL · Entity 163968 | Director | June 30, 2017 | July 05, 2017 |
| Tevogen Inc.LGST · Entity 7276 | Chief Financial Officer | June 07, 2023 | June 14, 2023 |
| Unrivaled Brands, Inc.UNRV · Entity 123632 | Director · CEO and President | June 07, 2021 | July 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aqua Metals, Inc.
Report date June 15, 2018 · Filed June 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,500 |
Last balance in matching sequence
After 2018-06-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-06-15 · Purchase · Acquired 2,500 · Balance 157,500 F1: Includes 150,000 shares underlying restricted stock units ("RSUs") that are not yet vested and deliverable. 50,000 of the RSU's shall vest and be delivered on April 12, 2019, 4,167 of the RSUs shall vest and be delivered each month thereafter, and 4,159 of the RSUs shall vest and be delivered on April 12, 2021. Row 2 · 2018-06-18 · Purchase · Acquired 5,000 · Balance 162,500 F1: Includes 150,000 shares underlying restricted stock units ("RSUs") that are not yet vested and deliverable. 50,000 of the RSU's shall vest and be delivered on April 12, 2019, 4,167 of the RSUs shall vest and be delivered each month thereafter, and 4,159 of the RSUs shall vest and be delivered on April 12, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 150,000 shares underlying restricted stock units ("RSUs") that are not yet vested and deliverable. 50,000 of the RSU's shall vest and be delivered on April 12, 2019, 4,167 of the RSUs shall vest and be delivered each month thereafter, and 4,159 of the RSUs shall vest and be delivered on April 12, 2021.
Beeline Holdings, Inc.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 130,000 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Grant · Acquired 50,000 · Balance 130,000 F1: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Special Committee of the Board of Directors composed of three non-employee directors. The units shall vest on the earlier of (i) September 8, 2027 or (ii) the disbanding of the Issuer's Special Committee of the Board of Directors, subject to continued service on the Board of Directors of the Company on the applicable vesting date. The grant of restricted stock units was made under the Issuer's Amended and Restated 2025 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Special Committee of the Board of Directors composed of three non-employee directors. The units shall vest on the earlier of (i) September 8, 2027 or (ii) the disbanding of the Issuer's Special Committee of the Board of Directors, subject to continued service on the Board of Directors of the Company on the applicable vesting date. The grant of restricted stock units was made under the Issuer's Amended and Restated 2025 Equity Incentive Plan.
CDT Equity Inc.
Report date February 02, 2022 · Filed February 11, 2022
This filing explicitly reported no securities owned.
Endovia Health Sciences, Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2036-06-08 | Direct | 500,000 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 500,000 · Balance 500,000 F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan, and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan, and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options are fully vested.
FORUM MARKETS Inc
Report date September 04, 2023 · Filed September 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2033-09-04 | Direct | 15,000 |
Reported balance
After 2023-09-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-04 · Grant · Acquired 15,000 · Balance 15,000 F1: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F2: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2023-09-04 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
F2: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.
Innovation1 Biotech Inc.
Report date November 01, 2024 · Filed February 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series C Senior Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Camden Capital LLC | Not disclosed |
Reported balance
Holding disclosure · report date 2024-11-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F3: Conversion Price is $0.000000586216897634410. F1: Reporting Person holds 600,000 shares of Series C Senior Convertible Preferred Stock. Each share of Series C Senior Convertible Preferred Stock is convertible into shares of the Issuer's common stock at any time by dividing the Stated Value of $0.001 by the Conversion Price of $0.000000586216897634410. F2: Represents shares of Series C Senior Convertible Preferred Stock held by Camden Capital LLC, an entity which the Reporting Person holds voting and investment control. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting Person holds 600,000 shares of Series C Senior Convertible Preferred Stock. Each share of Series C Senior Convertible Preferred Stock is convertible into shares of the Issuer's common stock at any time by dividing the Stated Value of $0.001 by the Conversion Price of $0.000000586216897634410.
F2: Represents shares of Series C Senior Convertible Preferred Stock held by Camden Capital LLC, an entity which the Reporting Person holds voting and investment control.
F3: Conversion Price is $0.000000586216897634410.
OS Therapies Inc
Report date September 29, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Lara Knuettel Revocable Trust | 20,000 |
Reported balance
Holding disclosure · report date 2026-09-29 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,000 F1: The reporting person is the co-trustee of the Lara Knuettel Revocable Trust and may be deemed to beneficially own the shares of common stock held of record by such trust. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is the co-trustee of the Lara Knuettel Revocable Trust and may be deemed to beneficially own the shares of common stock held of record by such trust. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
OceanTech Acquisitions I Corp.
Report date March 13, 2023 · Filed April 21, 2023
This filing explicitly reported no securities owned.
Relativity Acquisition Corp
Report date February 10, 2022 · Filed February 10, 2022
This filing explicitly reported no securities owned.
SCWorx Corp.
Report date November 26, 2019 · Filed November 29, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,393 |
Reported balance
After 2019-11-26 transaction · row 1
1 source rowRow 1 · 2019-11-26 · Grant · Acquired 50,000 · Balance 63,393 |
SPINDLE, INC.
Report date June 30, 2017 · Filed July 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 530,347 |
Reported balance
After 2017-06-30 transaction · row 1
1 source rowRow 1 · 2017-06-30 · Grant · Acquired 44,118 · Balance 530,347 F1: Shares issued in lieu of cash compensation for Board of Director services. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares issued in lieu of cash compensation for Board of Director services.
Tevogen Inc.
Report date June 07, 2023 · Filed June 14, 2023
This filing explicitly reported no securities owned.
Unrivaled Brands, Inc.
Report date June 07, 2021 · Filed July 12, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,850,000 |
Reported balance
After 2021-06-07 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2021-06-07 · Grant · Acquired 1,500,000 · Balance 1,850,000 F1: The shares of common stock vest in six equal installments, with the first installment vesting on the June 7, 2021, and the remaining installments vesting on every three-month anniversary thereafter; provided the reporting person is an employee of the issuer on the applicable vesting date. F2: This amendment is being filed to reflect the inadvertent omission of shares of common stock already held by the reporting person, which should have been added to the number of shares reported in Table I, Item 5, which number was originally reported as 1,500,000. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock vest in six equal installments, with the first installment vesting on the June 7, 2021, and the remaining installments vesting on every three-month anniversary thereafter; provided the reporting person is an employee of the issuer on the applicable vesting date.
F2: This amendment is being filed to reflect the inadvertent omission of shares of common stock already held by the reporting person, which should have been added to the number of shares reported in Table I, Item 5, which number was originally reported as 1,500,000.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Pelthos Therapeutics Inc.
Report date May 22, 2026 · Filed May 26, 2026
Section 16 reporting ended · disclosed 2026-05-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,525 |
Reported balance
After 2026-05-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-22 · Disposition to issuer · Disposed 13,947 · Balance 19,525 F1: Represents the forfeiture and cancellation of unvested restricted stock units ("RSUs") of Pelthos Therapeutics Inc. (the "Issuer"), for no consideration pursuant to that certain Separation Agreement entered into on May 15, 2026 (the "Separation Agreement") in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer. F2: The Separation Agreement provides for the acceleration of vesting of 19,525 RSUs out of the 33,472 previously reported RSUs granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of common stock, par value, $0.0001 per share ("Common Stock"), subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The 19,525 unvested RSUs became fully vested on May 22, 2026 upon expiration of the revocation period in the Separation Agreement. The transaction is exempt under Rule 16b-3(d). The acceleration does not represent a new grant of RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Lara Knuettel Revocable Trust | 11,316 |
Reported balance
After 2026-05-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-05-22 · Sale · Disposed 1,500 · Balance 11,316 F3: Represents an open market sale of the Lara Knuettel Revocable (the "Trust") on May 22, 2026. This transaction was executed in multiple trades at prices ranging from $26.66 to $27.16. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected F4: Francis Knuettel II is the co-trustee of the Trust and manager of Camden Capital LLC ("Camden"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.50 · Expires 2035-07-02 | Direct | 59,500 |
Reported balance
After 2026-05-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-22 · Grant · Acquired 59,500 · Balance 59,500 F5: Represents the acceleration of vesting of stock options pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer. The unvested stock options became fully vested and exercisable on May 22, 2026. The transaction is exempt under Rule 16b-3(d). This acceleration does not represent a new grant of options. The stock options may be exercised only until January 15, 2027, subject to the terms of the 2023 Plan and the Separation Agreement. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.50 · Expires 2035-07-02 | Direct | 0 |
Reported balance
After 2026-05-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-22 · Disposition to issuer · Disposed 42,500 · Balance 0 F6: Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectBy Camden Capital LLC | 10,000 |
Reported balance
Holding disclosure · report date 2026-05-22 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 10,000 F4: Francis Knuettel II is the co-trustee of the Trust and manager of Camden Capital LLC ("Camden"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the forfeiture and cancellation of unvested restricted stock units ("RSUs") of Pelthos Therapeutics Inc. (the "Issuer"), for no consideration pursuant to that certain Separation Agreement entered into on May 15, 2026 (the "Separation Agreement") in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.
F2: The Separation Agreement provides for the acceleration of vesting of 19,525 RSUs out of the 33,472 previously reported RSUs granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of common stock, par value, $0.0001 per share ("Common Stock"), subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The 19,525 unvested RSUs became fully vested on May 22, 2026 upon expiration of the revocation period in the Separation Agreement. The transaction is exempt under Rule 16b-3(d). The acceleration does not represent a new grant of RSUs.
F3: Represents an open market sale of the Lara Knuettel Revocable (the "Trust") on May 22, 2026. This transaction was executed in multiple trades at prices ranging from $26.66 to $27.16. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected
F4: Francis Knuettel II is the co-trustee of the Trust and manager of Camden Capital LLC ("Camden"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.
F5: Represents the acceleration of vesting of stock options pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer. The unvested stock options became fully vested and exercisable on May 22, 2026. The transaction is exempt under Rule 16b-3(d). This acceleration does not represent a new grant of options. The stock options may be exercised only until January 15, 2027, subject to the terms of the 2023 Plan and the Separation Agreement.
F6: Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2016 Filed Sep 13, 2016 21:55 UTC | SPINDLE, INC. SPDL · Entity 163968 | GrantCommon Stock | 148,148 | $0.14 | $19,999.98 |
DisclosureSEC source: 0001393905-16-001040 · primary_doc.xml · nonDerivative · entry 1 Francis Knuettel II · CIK 0001433316 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 2 Disclosed balance after: 708,148 F1 · shares: Shares purchased in a private-party transaction. F2 · ownership.nature: Indirect beneficial ownership - shares held in entities in which Mr. Knuettel has control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.